Enterprise Value

369.6M

Cash

120.1M

Avg Qtr Burn

N/A

Short % of Float

10.37%

Insider Ownership

0.68%

Institutional Own.

93.32%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CRB-701 (Nectin-4 ADC) Details
Solid tumor/s, Urothelial cancer

Phase 1

Data readout

Phase 1

Initiation

Lenabasum Details
Genetic disorder, Chronic inflammatory disorder, Rare genetic disease, Inflammatory disease

Failed

Discontinued

Lenabasum Details
Cystic fibrosis

Failed

Discontinued

Lenabasum Details
Systemic sclerosis

Failed

Discontinued

Failed

Discontinued